Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory approval Strong balance sheet expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch BRISBANE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2026.